secwatch.observer — SEC 8-K summary
======================================

Issuer:     UroGen Pharma Ltd. (URGN)
CIK:        0001668243
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001193125-23-141462
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

UroGen Pharma Q1 2023 JELMYTO revenue $17.2M (+27% YoY); net loss $30.2M
------------------------------------------------------------------------

- JELMYTO net product revenue $17.2M, up ~27% from $13.6M in Q1 2022.
- Net loss $30.2M ($1.30 per share) vs $28.4M ($1.25 per share) in Q1 2022.
- Cash and marketable securities $75.2M as of March 31, 2023.
- Reiterated FY 2023 JELMYTO revenue guidance $76-86M; operating expenses $135-145M.
- Topline data from ENVISION and ATLAS trials for UGN-102 expected summer 2023; NDA submission planned for 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523141462/0001193125-23-141462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1668243/000119312523141462/d365198d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-141462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer